European Pharmaceutical Review

MAY 7, 2024

percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. by 2029 appeared first on European Pharmaceutical Review. A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 The market is anticipated to value $1139.4 Eli Lilly and Company and Sandoz.

Vaccines 52

Vaccines Compounding Immunization FDA 52

Pharmaceutical Technology

APRIL 28, 2023

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Dosage 52

Dosage Compounding Labelling FDA 52

Pharmaceutical Technology

MAY 12, 2023

GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). GlobalData analysts predict the total revenue to be generated from currently marketed Seagen ADCs to be roughly $30bn through 2029. targeting ADC.

Chemotherapy 64

Chemotherapy Compounding 64

pharmaphorum

DECEMBER 20, 2022

He said ensifentrine will “change the treatment paradigm” for COPD by providing bronchodilation and anti-inflammatory properties in one compound. Shares in Verona popped on the news, rising more than 40% to approach $19.50 and drive the company’s market cap to almost $1.5

Compounding 57

Compounding 57

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. billion in 2029, although its sales growth is likely to continue beyond 2029. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9

Labelling 52

Labelling Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 3, 2023

According to GlobalData’s patient-based forecasts, infliximab biosimilars were anticipated to grow a notable compound annual growth rate (CAGR) of 14% from 2019 to 2029 in Remicade’s leading immunology indications, CD and UC.

Compounding 52

Compounding 52

PharmaShots

FEBRUARY 22, 2023

In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.

Insurance 64

Insurance Compounding Dosage Communication 64